These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 15509511

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.
    Clin Cancer Res; 2006 Nov 01; 12(21):6523-31. PubMed ID: 17085667
    [Abstract] [Full Text] [Related]

  • 3. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
    Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG, Hoshida T, Fukuyama S, Hamada H, Matsuno S.
    Cancer Gene Ther; 2006 Mar 01; 13(3):242-52. PubMed ID: 16179928
    [Abstract] [Full Text] [Related]

  • 4. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 5. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 01; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 8. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 01; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 9. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
    Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, Todoroki T, Tanaka N, Hamada H, Yokoyama KK.
    Cancer Res; 2003 Aug 01; 63(15):4434-40. PubMed ID: 12907616
    [Abstract] [Full Text] [Related]

  • 10. [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
    Wang WD, Chen ZT, Li DZ, Duan YZ, Wang ZX, Cao ZH.
    Ai Zheng; 2004 Jul 01; 23(7):788-93. PubMed ID: 15248913
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC, Nie MM, Yang JM, Su CQ, Sun LC, Qian YZ, Sham J, Fang GE, Wu MC, Qian QJ.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):943-8. PubMed ID: 15329284
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J, Cho JY, Kim JH, Jung KC, Yun CO.
    Cancer Gene Ther; 2002 Sep 02; 9(9):725-36. PubMed ID: 12189522
    [Abstract] [Full Text] [Related]

  • 13. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar 02; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.
    Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S, Chen S, Rom WN, Hay JG.
    Gene Ther; 2005 Jun 02; 12(11):911-7. PubMed ID: 15690061
    [Abstract] [Full Text] [Related]

  • 15. [Oncostatin M gene therapy in mice bearing lung adenocarcinoma xenograft using a hypoxia/radiation dual-sensitive promoter].
    Wang WD, Chen ZT, Li DZ, Duan YZ, Wang ZX, Cao ZH.
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr 02; 27(4):240-3. PubMed ID: 15144614
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.
    Cancer Biol Ther; 2010 Aug 01; 10(3):242-50. PubMed ID: 20574150
    [Abstract] [Full Text] [Related]

  • 18. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M, Murata T, Endo S, Hamada H, Hyodo I, Yokoyama KK.
    Cancer Gene Ther; 2009 Feb 01; 16(2):126-36. PubMed ID: 18818710
    [Abstract] [Full Text] [Related]

  • 19. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K.
    Gene Ther; 2005 Nov 01; 12(22):1608-17. PubMed ID: 16034456
    [Abstract] [Full Text] [Related]

  • 20. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM.
    Cancer Res; 2002 Jun 15; 62(12):3438-47. PubMed ID: 12067986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.